

Drug name	Formulation	Routine adult dosage	Altered dosages	
<i>NS5A inhibitor</i>				
Daclatasvir	30-mg tablet or 60-mg tablet	60 mg daily	Impaired renal function	No dose adjustment
			Impaired hepatic function	No dose adjustment
			Pregnancy and lactating women	Contraindicated
			Co-administration with strong CYP3A inhibitors <sup>a</sup>	30 mg daily
			Co-administration with moderate CYP3A inducers <sup>b</sup>	90 mg daily
<b>Multiple drug classes in fixed-dose combination</b>				
<i>NS3/4A protease inhibitor + NS5A inhibitor</i>				
Ombitasvir–paritaprevir–ritonavir	12.5/75/50-mg tablet	25/150/100 mg daily (two tablets daily)	Impaired renal function	No dose adjustment Suitable for use in ESRD/haemodialysis
			Impaired hepatic function	No dose adjustment in mild (Child-Pugh A) hepatic impairment Contraindicated in moderate (Child Pugh B) and severe (Child-Pugh C) hepatic impairment
			Pregnancy and lactating women	Pregnancy category B Pregnancy category X, if co-administered with RBV
Grazoprevir–elbasvir	100/50-mg tablet	100/50 mg daily (one tablet daily)	Impaired renal function	No dose adjustment Suitable for use in ESRD/hemodialysis
			Impaired hepatic function	No dose adjustment in mild (Child-Pugh A) hepatic impairment Contraindicated in moderate (Child Pugh B) and severe (Child-Pugh C) hepatic impairment
			Pregnancy and lactating women	No data
<i>NS5B polymerase inhibitor + NS5A inhibitor</i>				
Sofosbuvir–ledipasvir	400/90-mg tablet	400/90 mg daily (one tablet daily)	Impaired renal function	No dose adjustment for GFR > 30 ml/minute No dose recommendation for those with GFR < 30 ml/minute or with ESRD/hemodialysis
			Impaired hepatic function	No dose adjustment
			Pregnancy and lactating women	Pregnancy category B
Sofosbuvir–velpatasvir	400/100-mg tablet	400/100 mg daily (one table daily)	Impaired renal function	No dose adjustment for GFR > 50 ml/minute
			Impaired hepatic function	No dose adjustment in mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment
			Pregnancy and lactating women	No data

<sup>a</sup>For example, ritonavir-boosted atazanavir, some azoles, and clarithromycin.

<sup>b</sup>For example, efavirenz, dexamethasone, and nafcillin.

Abbreviations: PEG-IFN: pegylated interferon; RBV: ribavirin; CrCl: creatinine clearance; GFR: glomerular filtration rate; ESRD: end-stage renal disease.

Source: Data compiled from AbbVie (2015), Bristol-Myers Squibb (2015a), Bristol-Myers Squibb (2015b), Charlton *et al.* (2015), Curry *et al.* (2015), Feld *et al.* (2015), Foster *et al.* (2015), Gilead Sciences (2015a), Gilead Sciences (2015b), Jacobson *et al.* (2015), Merck (2016), Merck (2015), Pockros *et al.*, (2015), Roth *et al.* (2015), Vertex Pharmaceuticals (2013).